Tixagevimab/cilgavimab
< Tixagevimab
Tixagevimab (teal, right) and cilgavimab (purple, left) binding the spike protein RBD. From PDB: 7L7E. | |
| Combination of | |
|---|---|
| Tixagevimab | Monoclonal antibody |
| Cilgavimab | Monoclonal antibody |
| Clinical data | |
| Trade names | Evusheld |
| Other names | AZD7442 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a621058 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intramuscular |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Drug class | Antiviral |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6488H10034N1746O2038S50 |
| Molar mass | 146706.82 g·mol−1 |
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Drug class | Antiviral |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6626H10218N1750O2078S44 |
| Molar mass | 149053.44 g·mol−1 |
Tixagevimab/cilgavimab, sold under the brand name Evusheld, is a combination of two human monoclonal antibodies, tixagevimab (AZD8895) and cilgavimab (AZD1061) targeted against the surface spike protein of SARS-CoV-2 used to prevent COVID-19. It is being developed by British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca. It is co-packaged and given as two separate consecutive intramuscular injections (one injection per monoclonal antibody, given in immediate succession).